Early interim PET scan in Hodgkin lymphoma: Where do we stand?

Andrea Gallamini*, Martin Hutchings, Abraham Avigdor, Aaron Polliack

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Positron emission tomography using [18F]-fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.

Original languageEnglish
Pages (from-to)659-662
Number of pages4
JournalLeukemia and Lymphoma
Issue number4
StatePublished - Apr 2008
Externally publishedYes


  • ABVD
  • Interim
  • Lymphoma
  • PET
  • Prognosis


Dive into the research topics of 'Early interim PET scan in Hodgkin lymphoma: Where do we stand?'. Together they form a unique fingerprint.

Cite this